Identity
- Security key
- 12647
- Ticker
- BLRX
- Type
- ADRC — American Depository Receipt Common
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2011-07-25
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- BLRX
Detail
Enriched 2026-08-14 20:47
- Market cap
- $11,705,150.33
- Shares outstanding (class)
- 4,368,295
- Shares outstanding (weighted)
- 4,351,357
- SIC
- —
- Employees
- 24
- Location
- —
- Homepage
- https://www.biolinerx.com
- Description
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Market cap and share counts drift.